New York, NY -- (SBWIRE) -- 12/27/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Array Biopharma Inc(NASDAQ:ARRY), Chelsea Therapeutics International Ltd (NASDAQ:CHTP), Mast Therapeutics Inc (NYSEMKT:MSTX), VIVUS, Inc (NASDAQ:VVUS)
Array Biopharma Inc(NASDAQ:ARRY ) showed a volume of 1.37 million shares by the end of last trade whereas the average volume of the stock remained 1.73 million shares. The stock opened the session at $4.80 but then moved to $4.71. At that price, the stock showed a negative performance of -1.67%. Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases. The drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target pathways. The Company’s drug candidates include AMG 151, MEK162, ARRY-380, ARRY-520, ARRY-543 and ARRY-614.
Will ARRY Get Buyers Even After The Recent Rally? Find Out Here
Chelsea Therapeutics International Ltd (NASDAQ:CHTP) opened the session at $4.50 and closed the session at $4.41. The stock showed a negative performance of -0.90% in previous trading session. Traded with volume of 1.37 million shares in the prior session and the average volume of the stock remained 1.69 million shares. Chelsea Therapeutics International, Ltd. is a development stage pharmaceutical company that focuses on acquiring, developing and commercializing products for the treatment of a variety of human diseases. The Company is developing a therapeutic agent for the treatment of symptomatic neurogenic orthostatic hypotension (NOH), associated with primary autonomic failure and falls related to NOH in Parkinson’s Disease (PD), as well as other norepinephrine-related conditions and diseases,
Has CHTP Found The Bottom And Ready To Gain Momentum? Find Out Here
Mast Therapeutics Inc (NYSEMKT:MSTX) opened the session at $0.44 and closed the session at $0.446. The stock showed a positive performance of 2.51% in previous trading session. Traded with volume of 1.37 million shares in the prior session and the average volume of the stock remained 1.14 million shares. The beta of the stock remained 1.07. Mast Therapeutics, Inc., formerly ADVENTRX Pharmaceuticals, Inc., is a development-stage company biopharmaceutical company focused on developing product candidates. The Company's product candidate is ANX-188, a rheologic, antithrombotic and cytoprotective agent that improves microvascular blood flow and has application in treating a range of diseases and conditions, such as complications arising from sickle cell disease.
Why Should Investors Buy MSTX After The Recent Gain? Just Go Here and Find Out
VIVUS, Inc (NASDAQ:VVUS) the stock advanced 0.11% and finished the session at $9.33. Traded with volume of 1.36 million shares in the prior session and the average volume of the stock remained 1.71 million shares. The beta of the stock remained 1.33. VIVUS, Inc. is a biopharmaceutical company. It commercializes and develops therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health. Its drug, Qsymia (phentermine and topiramate extended-release) was approved by the the United States Food and Drug Administration (FDA) for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 or greater (obese),
Will VVUS Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)